KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Equity Average (2016 - 2025)

Historic Equity Average for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $21.1 billion.

  • Eli Lilly's Equity Average rose 5095.01% to $21.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 billion, marking a year-over-year increase of 5095.01%. This contributed to the annual value of $12.6 billion for FY2024, which is 1615.69% up from last year.
  • Eli Lilly's Equity Average amounted to $21.1 billion in Q3 2025, which was up 5095.01% from $17.1 billion recorded in Q2 2025.
  • Eli Lilly's Equity Average's 5-year high stood at $21.1 billion during Q3 2025, with a 5-year trough of $6.5 billion in Q1 2021.
  • For the 5-year period, Eli Lilly's Equity Average averaged around $11.5 billion, with its median value being $11.1 billion (2023).
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 11919.68% in 2021, then skyrocketed by 587.26% in 2023.
  • Over the past 5 years, Eli Lilly's Equity Average (Quarter) stood at $8.6 billion in 2021, then grew by 22.4% to $10.5 billion in 2022, then increased by 5.87% to $11.1 billion in 2023, then increased by 28.96% to $14.3 billion in 2024, then skyrocketed by 47.59% to $21.1 billion in 2025.
  • Its Equity Average was $21.1 billion in Q3 2025, compared to $17.1 billion in Q2 2025 and $15.1 billion in Q1 2025.